U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07046689) titled 'PET/CT for Trop2 ADC Response Evaluation Cancers' on June 19.
Brief Summary: To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.
Study Start Date: Nov. 01, 2024
Study Type: OBSERVATIONAL
Condition:
Breast Cancer
Trop2
PET/CT
Intervention:
DIAGNOSTIC_TEST: 68Ga-MY6349 PET/CT
Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging at baseline and following two cycles of Trop2-ADC therapy.
Recruitment Status: RECRUITING
Sponso...